Motzer, R. J., Escudier, B., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., . . . Tannir, N. M. (2020). Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial. Cancer, 126(18), 4156-4167. https://doi.org/10.1002/cncr.33033
Citácia podle Chicago (17th ed.)Motzer, Robert J., et al. "Nivolumab Versus Everolimus in Patients with Advanced Renal Cell Carcinoma: Updated Results with Long‐term Follow‐up of the Randomized, Open‐label, Phase 3 CheckMate 025 Trial." Cancer 126, no. 18 (2020): 4156-4167. https://doi.org/10.1002/cncr.33033.
Citácia podľa MLA (8th ed.)Motzer, Robert J., et al. "Nivolumab Versus Everolimus in Patients with Advanced Renal Cell Carcinoma: Updated Results with Long‐term Follow‐up of the Randomized, Open‐label, Phase 3 CheckMate 025 Trial." Cancer, vol. 126, no. 18, 2020, pp. 4156-4167, https://doi.org/10.1002/cncr.33033.